December 26, 2023 11:52 AM EST

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

Nicole DeFeudis

Editor

The FDA has added a black box warning to Johnson & Johnson and Legend Biotech’s CAR-T treatment Carvykti as the agency continues to investigate rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

Nicole DeFeudis

Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

At Jefferies, all that manufacturers want to talk about is GLP-1s

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?

Fol­low­ing FDA in­quiry in­to CAR-T safe­ty, agency adds warn­ing on sec­ondary can­cers for Carvyk­ti

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

Patient dies in Neurogene's Rett syndrome study

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

At Jefferies, all that manufacturers want to talk about is GLP-1s

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?